Trial Profile
A Phase 3, Multi-Center, Randomized, Double-Blind, Efficacy And Safety Study Of Monotherapy Sitaxsentan Sodium Versus Combination Therapy With Sitaxsentan Sodium And Sildenafil Citrate In Subjects With Pulmonary Arterial Hypertension Who Have Completed Study B1321001 (NCT00795639)
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 24 Aug 2016
Price :
$35
*
At a glance
- Drugs Sildenafil (Primary) ; Sitaxentan (Primary)
- Indications Pulmonary arterial hypertension
- Focus Registrational; Therapeutic Use
- Sponsors Pfizer
- 12 May 2014 New trial record
- 18 Apr 2011
- 08 Mar 2011